- BIOEMTECH has entered a strategic supply agreement with NorthStar Medical Radioisotopes to secure Actinium-225 (Ac-225) for preclinical research use.
- Initial deliveries are scheduled to begin in Q1 2026, supporting consistent isotope access for targeted radiotherapeutic studies.
BIOEMTECH has signed a strategic supply agreement with NorthStar Medical Radioisotopes to secure Actinium-225 (Ac-225) for use in preclinical studies conducted by its customers. The agreement is designed to provide consistent access to the alpha-emitting isotope used in the development and evaluation of targeted radiotherapeutics.
Under the agreement, NorthStar will provide regular, scheduled deliveries of Ac-225 tailored to preclinical dosing and research timelines. Initial deliveries are expected to begin in the first quarter of 2026, with volumes scalable based on research demand. Material will be supplied under validated procedures that meet applicable regulatory and transport standards for research isotopes.
BIOEMTECH stated that reliable isotope access is intended to accelerate preclinical radiopharmaceutical development by reducing supply bottlenecks and ensuring timely, compliant access to high-quality material. The companies will coordinate logistics and technical support to align isotope delivery with BIOEMTECH’s preclinical imaging services and customer study timelines.
“Reliable isotope supply is a major bottleneck in early radiopharmaceutical development. This agreement enables our customers to run more predictable, higher-impact studies using our imaging platforms.”
said Dr. Maritina Rouchota, Chief Quality Officer of BIOEMTECH
Through BIOEMTECH’s ordering channels, customers and partners will be able to request Ac-225 supply, while NorthStar will provide isotope-specific documentation and handling guidance to support laboratory safety and study reproducibility.
